Both signature genes, CDK2 and CCND1, possess a potential clinical value in effectively distinguishing HF and KF patients from healthy controls, offering promising diagnostic biomarkers for cardiorenal disease. This evidence concerns the gene CDK2 and hydrops fetalis.